Skip to main content

Table 2 Crude association between hepatic adverse events and episodes groups over treatment arms

From: Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Episodes groups

COR (95% CI) with hepatic adverse events

Elevated ALT

Elevated AST

Elevated ALP

Elevated direct bilirubin

Elevated total bilirubin

AL

First treatment

1

1

1

1

1

Retreatment

0.25

(0.08; 0.72) *

0.18

(0.07;0.45) ***

2.09

(0.58; 7.58)

1.80

(0.99; 3.30)

2.13

(1.15; 3.92) *

PA

First treatment

1

1

1

1

1

Retreatment

0.33

(0.14; 0.76) *

0.65

(0.28; 1.53)

1.17

(0.33; 4.04)

1.66

(0.83; 3.34)

1.36

(0.71; 2.60)

  1. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; p: p-value; SD: Standard deviation; COR: crude odds ratio; CI: Confidence interval; AL: artemether–lumefantrine; PA: pyronaridine-artesunate
  2. * p < 0.05
  3. ** p < 0.01
  4. *** p < 0.001
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us